169 related articles for article (PubMed ID: 36660119)
1. The associations between central serous chorioretinopathy and muscle relaxants: A case-control study.
Jain M; Garg SJ; Khan M; Chaudhary V; Zeraatkar D; Kurian D; Lal S
Taiwan J Ophthalmol; 2022; 12(4):415-422. PubMed ID: 36660119
[TBL] [Abstract][Full Text] [Related]
2. A multicentre study of the risk factors associated with recurrence of central serous chorioretinopathy.
Zhou X; Komuku Y; Araki T; Hozumi K; Terasaki H; Miki A; Kuwayama S; Niki M; Matsubara H; Kinoshita T; Nishi T; Gomi F
Acta Ophthalmol; 2022 Dec; 100(8):e1729-e1736. PubMed ID: 35633142
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies of 1-(2,3-dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1- propanone hydrochloride (AD-2239), a centrally acting muscle relaxant.
Ito T; Hori M; Furukawa K; Karasawa T; Kadokawa T
Arch Int Pharmacodyn Ther; 1985 May; 275(1):105-22. PubMed ID: 3839647
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011.
Li Y; You QS; Wei WB; Xu J; Chen CX; Wang YX; Xu L; Jonas JB
Acta Ophthalmol; 2016 Jun; 94(4):386-90. PubMed ID: 26928876
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids usage and central serous chorioretinopathy: a meta-analysis.
Ge G; Zhang Y; Zhang Y; Xu Z; Zhang M
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):71-77. PubMed ID: 31734720
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats.
Matsunaga M; Uemura Y; Yonemoto Y; Kanai K; Etoh H; Tanaka S; Atsuta Y; Nishizawa Y; Yamanishi Y
Jpn J Pharmacol; 1997 Mar; 73(3):215-20. PubMed ID: 9127816
[TBL] [Abstract][Full Text] [Related]
7. Rapid simultaneous determination of eperisone, tolperisone, and tizanidine in human serum by using a MonoSpin® C18 extraction column and liquid chromatography/tandem mass spectrometry.
Miura N; Saito T; Taira T; Yamagiwa T; Morita S; Inokuchi S
J AOAC Int; 2014; 97(6):1546-51. PubMed ID: 25632432
[TBL] [Abstract][Full Text] [Related]
8. Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Farkas S; Berzsenyi P; Kárpáti E; Kocsis P; Tarnawa I
J Pharmacol Toxicol Methods; 2005; 52(2):264-73. PubMed ID: 16125625
[TBL] [Abstract][Full Text] [Related]
9. Oral muscle relaxant may induce immediate allergic reactions.
Hur GY; Hwang EK; Moon JY; Ye YM; Shim JJ; Park HS; Kang KH
Yonsei Med J; 2012 Jul; 53(4):863-5. PubMed ID: 22665359
[TBL] [Abstract][Full Text] [Related]
10. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy.
Schubert C; Pryds A; Zeng S; Xie Y; Freund KB; Spaide RF; Merriam JC; Barbazetto I; Slakter JS; Chang S; Munch IC; Drack AV; Hernandez J; Yzer S; Merriam JE; Linneberg A; Larsen M; Yannuzzi LA; Mullins RF; Allikmets R
Hum Mutat; 2014 Jul; 35(7):859-67. PubMed ID: 24665005
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of choroidal blood flow parameters in optical coherence tomography and angiography in central serous chorioretinopathy.
Hwang BE; Kwak JH; Kim JY; Kim RY; Kim M; Park YG; Park YH
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2111-2120. PubMed ID: 35201403
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients.
Ersoz MG; Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Br J Ophthalmol; 2019 Jun; 103(6):725-729. PubMed ID: 30002072
[TBL] [Abstract][Full Text] [Related]
13. Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy.
Terao N; Koizumi H; Kojima K; Kusada N; Nagata K; Yamagishi T; Yoneda K; Yoshii K; Kinoshita S; Sotozono C
Br J Ophthalmol; 2020 Sep; 104(9):1260-1265. PubMed ID: 31780441
[TBL] [Abstract][Full Text] [Related]
14. Association of Corticosteroid Use With Incidence of Central Serous Chorioretinopathy in South Korea.
Rim TH; Kim HS; Kwak J; Lee JS; Kim DW; Kim SS
JAMA Ophthalmol; 2018 Oct; 136(10):1164-1169. PubMed ID: 30098167
[TBL] [Abstract][Full Text] [Related]
15. Systemic factors associated with central serous chorioretinopathy in Koreans.
Eom Y; Oh J; Kim SW; Huh K
Korean J Ophthalmol; 2012 Aug; 26(4):260-4. PubMed ID: 22870024
[TBL] [Abstract][Full Text] [Related]
16. CHOROIDAL THICKNESS OF CENTRAL SEROUS CHORIORETINOPATHY SECONDARY TO CORTICOSTEROID USE.
Honda S; Miki A; Kusuhara S; Imai H; Nakamura M
Retina; 2017 Aug; 37(8):1562-1567. PubMed ID: 27787451
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective separation and simultaneous determination of tolperisone and eperisone in rat plasma by LC-MS/MS.
Nageswara Rao R; Satyanarayana Raju S
Chirality; 2013 Oct; 25(10):622-7. PubMed ID: 23840024
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India.
Majumder PD; Menia N; Sudharshan S; Rao C; Ganesh SK; Biswas J
Indian J Ophthalmol; 2019 Feb; 67(2):247-251. PubMed ID: 30672479
[TBL] [Abstract][Full Text] [Related]
19. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels.
Kocsis P; Farkas S; Fodor L; Bielik N; Thán M; Kolok S; Gere A; Csejtei M; Tarnawa I
J Pharmacol Exp Ther; 2005 Dec; 315(3):1237-46. PubMed ID: 16126840
[TBL] [Abstract][Full Text] [Related]
20. Biometric characteristics of eyes with central serous chorioretinopathy.
Oh JH; Oh J; Togloom A; Kim SW; Huh K
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1502-8. PubMed ID: 24550360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
